Menu Search
Equities

Centessa Pharmaceuticals PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
260:FRA

Centessa Pharmaceuticals PLC

Actions
  • Price (EUR)19.40
  • Today's Change-1.60 / -7.62%
  • Shares traded50.00
  • 1 Year change+19.75%
  • Beta1.5745
Data delayed at least 15 minutes, as of Feb 06 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

  • Revenue in USD (TTM)15.00m
  • Net income in USD-242.70m
  • Incorporated2020
  • Employees114.00
  • Location
    Centessa Pharmaceuticals PLC3Rd Floor, 1 Ashley RoadALTRINCHAM WA14 2DTUnited KingdomGBR
  • Websitehttps://www.centessa.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.